Ad-hoc | 10 April 2014 13:32


WILEX AG plans reduction of share capital

WILEX AG  / Key word(s): Capital Reorganisation

10.04.2014 13:32

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

WILEX AG plans reduction of share capital

Munich, Germany, 10 April 2014. WILEX AG will publish its invitation to the
annual general meeting, which will be held on 23 May, 2014, in the Federal
Gazette on Monday, 14 April 2014. The agenda will include a draft
resolution of the Executive Management and Supervisory Board on an ordinary
reduction of WILEX AG share capital by EUR 23,456,628.00 to EUR
7,818,876.00 by consolidation of the issued no par value shares in a ratio
of 4:1 from 31,275,504 to 7,818,876 shares, pursuant to §§ 222 ff. of the
German Stock Corporation Act. To obtain an even ratio, three shares will be
surrendered free of charge by one shareholder prior to the reduction and
will be collected by the Company.

The reason for this measure is that for several months the price of WILEX
AG's shares was repeatedly below their nominal value. By consolidating four
no par value shares to one share the price of the WILEX share will be
significantly increased above the nominal value of one Euro. This gives
greater flexibility and transaction capacity to WILEX AG in respect of the
minimum issue price according to § 9, par. 1 of the German Stock
Corporation Act. No specific capital measures are currently planned, but
due to the financial and structural situation of the Company this
accounting measure is seen as urgently necessary. Being an accounting
measure, the reduction will result in a transfer from subscribed capital to
capital reserves on the equity and liabilities side of the balance sheet of
WILEX AG. This measure does not affect the value of the company.

The invitation to the annual general meeting of WILEX AG will be available
on 14 April, 2014 on the Company's website under
http://www.wilex.de/press-investors/annual-general-meeting/agm2014/.


---------------------------------------------------------------------------

Information and Explaination of the Issuer to this News:

About WILEX 

WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company develops diagnostic and therapeutic product
candidates based on antibodies and small molecules, which are available for
out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical
contract research services and an antibody drug conjugate (ADC) technology
platform. Our customers and partners include leading international
pharmaceutical companies. WILEX is listed at the Frankfurt Stock Exchange:
ISIN DE0006614720 / WKN 661472 / Symbol WL6. More information is available
at www.wilex.com

Contact                                 For press enquiries
WILEX AG                                MC Services AG
Corporate Communications                Katja Arnold (CIRO)
Sylvia Wimmer                           Tel.: +49 (0)89-41 31 38-126
Tel.: +49 (0)89-41 31 38-29             Tel.: +49-89-210 228-40
Email: investors[at]wilex.com           Mobil: +49 160 9360 3022
Grillparzerstr. 10, 81675 Munich,       E-Mail: katja.arnold[at]mc-
Germany                                 services.eu
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as 'estimates', 'believes', 'expects', 'may', 'will', 'should', 'future', 'potential' or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. 10.04.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: WILEX AG Grillparzerstr. 10 81675 München Germany Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: info@wilex.com Internet: www.wilex.com ISIN: DE0006614720 WKN: 661472 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------